Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 18, 2019 - Issue 11
Submit an article Journal homepage
609
Views
23
CrossRef citations to date
0
Altmetric
Original Research

Bullous pemphigoid induced by dipeptidyl peptidase-4 (DPP-4) inhibitors: a pharmacovigilance-pharmacodynamic/pharmacokinetic assessment through an analysis of the vigibase®

Carla CarnovaleUnit of Clinical Pharmacology Department of Biomedical and Clinical Sciences L. Sacco, “Luigi Sacco” University Hospital, Università di Milano, Milan, ItalyCorrespondence[email protected]
View further author information
,
Faizan MazharUnit of Clinical Pharmacology Department of Biomedical and Clinical Sciences L. Sacco, “Luigi Sacco” University Hospital, Università di Milano, Milan, ItalyView further author information
,
Elena ArzentonDepartment of Diagnostics and Public Health, Section of Pharmacology, University of Verona, Verona, ItalyView further author information
,
Ugo MorettiDepartment of Diagnostics and Public Health, Section of Pharmacology, University of Verona, Verona, ItalyView further author information
,
Marco PozziScientific Institute, IRCCS Eugenio Medea, Bosisio Parini, Lecco, ItalyView further author information
,
Giulia MosiniUnit of Clinical Pharmacology Department of Biomedical and Clinical Sciences L. Sacco, “Luigi Sacco” University Hospital, Università di Milano, Milan, ItalyView further author information
,
Olivia LeoniRegional Pharmacovigilance Center of Lombardy, Milan, ItalyView further author information
,
Marco ScatignaSpecialisation School of Clinical Pharmacology and Toxicology, Università degli Studi di Milano, Milan, ItalyView further author information
,
Emilio ClementiUnit of Clinical Pharmacology Department of Biomedical and Clinical Sciences L. Sacco, “Luigi Sacco” University Hospital, Università di Milano, Milan, Italy;Scientific Institute, IRCCS Eugenio Medea, Bosisio Parini, Lecco, ItalyView further author information
&
Sonia RadiceUnit of Clinical Pharmacology Department of Biomedical and Clinical Sciences L. Sacco, “Luigi Sacco” University Hospital, Università di Milano, Milan, ItalyView further author information
 show all
Pages 1099-1108 | Received 07 Jun 2019, Accepted 12 Sep 2019, Published online: 26 Sep 2019

  • Sagi L, Baum S, Agmon-Levin N, et al. Autoimmune bullous diseases the spectrum of infectious agent antibodies and review of the literature. Autoimmun Rev. 2011;10:527–535.
  • Yancey KB, Egan CA. Pemphigoid: clinical, histologic, immunopathologic, and therapeutic considerations. JAMA. 2000;284:350–356.
  • Setterfield J, Theron J, Vaughan RW, et al. Mucous membrane pemphigoid: HLA-DQB1*0301 is associated with all clinical sites of involvement and may be linked to antibasement membrane IgG production. Br J Dermatol. 2001;145:406–414.
  • Budinger L, Borradori L, Yee C, et al. Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls. J Clin Invest. 1998;102:2082–2089.
  • Okazaki A, Miyagawa S, Yamashina Y, et al. Polymorphisms of HLA-DR and -DQ genes in Japanese patients with bullous pemphigoid. J Dermatol. 2000;27:149–156.
  • Tan CW, Pang Y, Sim B, et al. The association between drugs and bullous pemphigoid. Br J Dermatol. 2017;176:549–551.
  • Stavropoulos PG, Soura E, Antoniou C. Drug-induced pemphigoid: a review of the literature. J Eur Acad Dermatol Venereol. 2014;28:1133–1140.
  • Siegel J, Totonchy M, Damsky W, et al. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. J Am Acad Dermatol. 2018;79:1081–1088.
  • Plaquevent M, Tetart F, Fardet L, et al. Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the french General Population. J Invest Dermatol. 2019;139(4):835–841.
  • Garcia-Diez I, Ivars-Lleo M, Lopez-Aventin D, et al. Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization. Int J Dermatol. 2018;57(7):810–816.
  • Gaudin O, Seta V, Alexandre M, et al. Gliptin accountability in mucous membrane pemphigoid induction in 24 out of 313 patients. Front Immunol. 2018;9:1030.
  • Kawaguchi Y, Shimauchi R, Nishibori N, et al. Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: a retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients. J Diabetes Investig. 2018. DOI:10.1111/jdi.12877.
  • Arai M, Shirakawa J, Konishi H, et al. Bullous pemphigoid and dipeptidyl peptidase 4 inhibitors: a disproportionality analysis based on the Japanese adverse drug event report database. Diabetes Care. 2018;41:e130–e2.
  • Kridin K, Cohen AD. Dipeptidyl-peptidase IV inhibitor-associated bullous pemphigoid: a systematic review and meta-analysis. J Am Acad Dermatol. 2018 ;pii: S0190-9622(18)32660-4. DOI:10.1016/j.jaad.2018.09.048.
  • Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3:153–165.
  • Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–1705.
  • Rasmussen HB, Branner S, Wiberg FC, et al. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat Struct Biol. 2003;10:19–25.
  • Lankas GR, Leiting B, Roy RS, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes. 2005;54:2988–2994.
  • Ohnuma K, Hosono O, Dang NH, et al. Dipeptidyl peptidase in autoimmune pathophysiology. Adv Clin Chem. 2011;53:51–84.
  • Forssmann U, Stoetzer C, Stephan M, et al. Inhibition of CD26/dipeptidyl peptidase IV enhances CCL11/eotaxin-mediated recruitment of eosinophils in vivo. J Immunol. 2008;181:1120–1127.
  • Siafis S, Papazisis G. Detecting a potential safety signal of antidepressants and type 2 diabetes: a pharmacovigilance-pharmacodynamic study. Br J Clin Pharmacol. 2018;84:2405–2414.
  • Bate A, Lindquist M, Edwards IR. The application of knowledge discovery in databases to post-marketing drug safety: example of the WHO database. Fundam Clin Pharmacol. 2008;22:127–140.
  • Uppsala Monitoring Centre Uppsala Monitoring Centre. [cited 2019 Feb 3]. Available from: https://signin.who-umc.org.
  • BRENDA. The comprehensive enzyme information system. [cited 2019 Feb 10]. Available from: https://www.brenda-enzymes.org/Accessed
  • BindingDB: A public database for medicinal chemistry, computational chemistry and systems pharmacology. [cited 2019 feb 12]. Available from: https://www.bindingdb.org/bind/index.jsp
  • The European Bioinformatics Institute ChEMBL database. [cited 2019 feb 11]. Available from: https://www.ebi.ac.uk/chembl/Accessed
  • KEGG LIGAND Database. [cited 2019 Feb 11]. Available from: https://www.genome.jp/kegg/ligand.html
  • The Metabolomics Innovation Centre. DrugBank. [cited 2019 Feb 11]. Available from: https://www.drugbank.ca
  • IDAAPM: integrated database of ADMET and adverse effects of predictive modeling based on FDA approved drug data. [cited 2019 Feb 11]. Available from: http://idaapm.helsinki.fi/Documentation
  • Garcia M, Aranburu MA, Palacios-Zabalza I, et al. Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database. J Clin Pharm Ther. 2016;41:368–370.
  • Bene J, Moulis G, Bennani I, et al. Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the french Pharmacovigilance Database. Br J Dermatol. 2016;175:296–301.
  • Benzaquen M, Borradori L, Berbis P, et al. Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: retrospective multicenter case-control study from France and Switzerland. J Am Acad Dermatol. 2018;78:1090–1096.
  • Varpuluoma O, Forsti AK, Jokelainen J, et al. Vildagliptin significantly increases the risk of bullous pemphigoid: a finnish nationwide registry study. J Invest Dermatol. 2018;138:1659–1661.
  • Faillie J-L. Case–non-case studies: principle, methods, bias and interpretation. Thérapie. 2019. pii: S0040-5957(19)30023-X. DOI:10.1016/j.therap.2019.01.006.
  • Dorn JM, Alpern M, McNulty C, et al. Sulfonamide Drug Allergy. Curr Allergy Asthma Rep. 2018. 6. 18(7):38.
  • Heymann WR. Bullae for you: the increasing importance and implications of drug-induced bullous pemphigoid. J Am Acad Dermatol. 2018;79(6):1026–1027.
  • Lloyd-Lavery A, Chi CC, Wojnarowska F, et al. The associations between bullous pemphigoid and drug use: a UK case-control study. JAMA Dermatol. 2013;149:58–62.
  • Varpuluoma O, Forsti AK, Jokelainen J, et al. Oral diabetes medications other than dipeptidyl peptidase 4 inhibitors are not associated with bullous pemphigoid: a Finnish nationwide case-control study. J Am Acad Dermatol. 2018;79:1034–8.e5.
  • Lee SG, Lee HJ, Yoon MS, et al. Association of dipeptidyl peptidase 4 inhibitor use with risk of bullous pemphigoid in patients with diabetes. JAMA Dermatol. 2019;155:172–177.
  • Gorrell MD, Wang XM, Park J, et al. Structure and function in dipeptidyl peptidase IV and related proteins. Boston, MA: Springer US; 2006. p. 45–54.
  • Holst JJ. The physiology and pharmacology of incretins in type 2 diabetes mellitus. Diabetes Obes Metab. 10:14–21.
  • Martin JH, Deacon CF, Gorrell MD, et al. Incretin-based therapies–review of the physiology, pharmacology and emerging clinical experience. Intern Med J. 2011;41:299–307.
  • Yu DM, Yao TW, Chowdhury S, et al. The dipeptidyl peptidase IV family in cancer and cell biology. Febs J. 2010;277:1126–1144.
  • Grimshaw CE, Jennings A, Kamran R, et al. Trelagliptin (SYR-472, Zafatek), novel once-weekly treatment for type 2 diabetes, inhibits dipeptidyl peptidase-4 (DPP-4) via a non-covalent mechanism. PLoS One. 2016;11:e0157509.
  • Biftu T, Sinha-Roy R, Chen P, et al. Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. J Med Chem. 2014;57:3205–3212.
  • Hughes TE, Russell ME, Bolognese L, et al. NVP-LAF237, a highly selective and long-acting dipeptidyl peptidase IV inhibitor. Diabetes. 2002;51(Suppl.2):A67. Abstract 272-OR.
  • Villhauer EB, Brinkman JA, Naderi GB, et al. 1-[[(3-hydroxy-1- adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem. 2003;46:2774–2789.
  • Brandt I, Joossens J, Chen X, et al. Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile). Biochem Pharmacol. 2005;70:134–143.
  • Boulton DWJCP. Clinical pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor. Clin Pharmacokinet. 2017;56(1):11–24.
  • Matteucci E, Giampietro O. Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme. Curr Med Chem. 2009;16:2943–2951.
  • Vora KA, Porter G, Peng R, et al. Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses. BMC Immunol. 2009;10:19.
  • Steeg C, Hartwig U, Fleischer B. Unchanged signaling capacity of mutant CD26/Dipeptidylpeptidase IV molecules devoid of enzymatic activity. Cell Immunol. 1995;164:311–315.
  • Coburn MC, Hixson DC, Reichner JS. In vitro immune responsiveness of rats lacking active dipeptidylpeptidase IV. Cell Immunol. 1994;158:269–280.
  • Tanaka S, Murakami T, Horikawa H, et al. Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV. Int J Immunopharmacol. 1997;19:15–24.
  • Kodera R, Chiba Y, Tamura Y, et al. [Clinical characteristics of bullous pemphigoid in elderly patients with type 2 diabetes mellitus: the association with the use of dipeptidyl peptidase-4 inhibitors]. Nihon Ronen Igakkai Zasshi. 2019;56:43–50.
  • Ujiie H, Muramatsu K, Mushiroda T, et al. HLA-DQB1*03:01 as a biomarker for genetic susceptibility to bullous pemphigoid induced by DPP-4 inhibitors. J Invest Dermatol. 2018;138:1201–1204.
  • Kushwaha RN, Haq W, Katti SB. Discovery of 17 gliptins in 17-years of research for the treatment of type 2 diabetes: a synthetic overview. J Chem Biol Interfaces. 2014;4(3):137–162.
  • Chen XW, He ZX, Zhou ZW, et al. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clin Exp Pharmacol Physiol. 2015;42(10):999–1024.
  • Hauben M, Aronson JK. Gold standards in pharmacovigilance: the use of definitive anecdotal reports of adverse drug reactions as pure gold and high-grade ore. Drug Saf. 2007;30:645–655.
  • Kirby MS, Dorso C, Wang A, et al. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin Sci (Lond). 2010;118(1):31–41.
  • Kalliokoski T, Kramer C, Vulpetti A, et al. Comparability of mixed IC50 data - a statistical analysis. PLoS One. 2013;8:e61007.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.